secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001297184-25-000048
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar Q2 2025 revenue $174.4M, GAAP EPS $0.64; BAQSIMI sales up 21%
-----------------------------------------------------------------------

- Net revenues $174.4M vs $182.4M YoY; GAAP net income $31.0M ($0.64 diluted EPS).
- Adjusted non-GAAP net income $40.9M ($0.85 diluted EPS) vs $48.7M ($0.94) YoY.
- BAQSIMI sales increased 21% YoY, cited as key revenue driver.
- Announced multi-year plan to quadruple manufacturing capacity at Rancho Cucamonga HQ.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718425000048/0001297184-25-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718425000048/amph-20250807x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-25-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer